Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revaccination of immunosuppressed patients with poor or no SARS-CoV-2 vaccine response
2021-003618-37Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of LVRNA021 in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Oslo University Hospital. Primary endpoint: SARS-CoV-2 SPIKE/RBD IgG antibody levels 4 weeks after third dose. Started Jun 2021; status: completed.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003618-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003618-37.